Skip to main content
. 2021 Dec 27;14(1):45. doi: 10.3390/pharmaceutics14010045

Figure 2.

Figure 2

Figure 2

Effect of MET+SM combination therapy on hepatic lipid storage: (A) TAG, (B) DAG, (C) arachidonic acid metabolites 14,15-EET and (D) 20-HETE, (E) fatty acid composition in liver DAG class (E,F) histology of liver tissue: liver sections of all three groups showed minimal alterations of the liver tissue—normally arranged liver with minimal macrophage aggregates and eosinophils in the portal space. Histochemically, in the HHTg/C group, the positivity for cholesterol esters/TAGs was estimated at <5%, and in the HHTg/MET and HHTg/MET+SM group, positivity was <1%; MA—myristic acid, PA—palmitic acid, POA—palmitoleic acid, SA—stearic acid, LA—linoleic acid, αLA—α-linoleic acid, AA—arachidonic acid, EPA—eicosapentaenoic acid, DHA—docosahexaenoic acid. Values are expressed as means ± SEM; n = 6 for HHTg/C, n = 7 for HHTg/MET, n = 8 for HHTg/MET+SM; * p < 0.05, ** p < 0.01 probability reflecting the effect of MET monotherapy vs. the control group without treatment; †† p < 0.01, ††† p < 0.001 probability reflecting the effect of MET therapy vs. MET+SM combination therapy.